Effect of Atorvastatin in patients with Rheumatoid Arthritis

Effect of (Atorvastatin) on welfare and reduction of disease severity and activity in patients with Rheumatoid Arthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014051817738N1

Enrollment

Registered

2014-10-25

Start date

2014-06-05

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis. seropositive rheumatoid arthritis

Interventions

Intervention 1: Atorvastatin with a dose of 40 mg once daily during 8 weeks in intervention group. Intervention 2: Placebo once daily during 8 weeks in control group.

Treatment - Drugs

Placebo

Atorvastatin with a dose of 40 mg once daily during 8 weeks in intervention group

Placebo once daily during 8 weeks in control group

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria : 1- Patients with Rheumatoid Arthritis basis on ACR2010 Criteria and with moderate to sever disease activity with DAS28 Score Exclusion Criteria : 1- age under 18 years old 2- disease duration more than 5 years 3- present use of Atorvastatin 4-Contraindication of Atorvastatin use consist of Hepatic or Renal failure 5- presence of each kind of cancer 6- Pregnancy

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
ESR : Erythrocyte Sedimentation Rate. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: mm/h and by Western Green Method.;Swelling Joint Count (SJC). Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: numerical Scale and by examination of physician.;Tender Joint Count (TJC). Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: numerical Scale and by examination of physician.;CRP : C Reactive Protein. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: Proportional Scale by blood sampling.;DAS28 Score. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: Standard DAS28 Questionnarie.	—

Measure

Time frame

ESR : Erythrocyte Sedimentation Rate. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: mm/h and by Western Green Method.;Swelling Joint Count (SJC). Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: numerical Scale and by examination of physician.;Tender Joint Count (TJC). Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: numerical Scale and by examination of physician.;CRP : C Reactive Protein. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: Proportional Scale by blood sampling.;DAS28 Score. Timepoint: Before Intervention and 8 weeks after intervention. Method of measurement: Standard DAS28 Questionnarie.

—

Secondary

Measure	Time frame
Myopathy. Timepoint: 3 weeks after beginning of study and after it during the study. Method of measurement: through history and question about muscular pain.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKarim Mowla

Ahvaz Jondishapour university of Medical Science

Mowla_k@yahoo.com+98 61 1374 3013

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026